Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The economic burden of Borderline Personality Disorder: direct and indirect costs, and evidence from evaluations of interventions.

Created on 16 Oct 2026

Authors

Monica Ghoyal, Greta Dertwinkel, Katie Nicol, Ruchika Gajwani, Manuela Deidda

Published in

Frontiers in psychiatry. Volume 17. Pages 1835343. Epub Sep 30, 2026.

Abstract

Borderline Personality Disorder (BPD) is characterized by longstanding patterns of difficulty in functioning, and when left untreated, BPD can impose a substantial financial burden on individuals and society, in terms of higher healthcare costs as well as broader societal costs.
To conduct a critical review of the direct and indirect costs related to BPD. Additionally, to critically evaluate the economic evidence on interventions for BPD.
A comprehensive search strategy was conducted across PsycINFO, PubMed, and SCOPUS. Studies were screened in two phases: an initial title and abstract review, followed by full-text screening against a predefined eligibility criteria.
Across 23 studies, high direct and indirect costs were consistently reported. Economic evaluations primarily examined established psychological interventions for BPD, such as Dialectical Behavior Therapy (DBT), Cognitive Behavior Therapy (CBT), and Schema-Focused Therapy (SFT), comparing costs and quality-of-life outcomes, with most demonstrating cost savings through reduced inpatient and emergency service use.
This review highlights the substantial economic burden of BPD, driven by high service use, productivity losses, and unmet needs. While interventions such as DBT, CBT and SFT show potential cost-effectiveness, inconsistent cost definitions and the omission of key components, including informal care and long-term impairment, likely lead to an underestimation of true costs. More comprehensive and standardized economic evaluations are needed.

PMID:
42877117
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 21
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement